Fig. 1From: Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trialHAQ-DI (a), FACIT-F (b), DLQI (c) change from baseline (weeks 16 and 24, overall population). *Statistically significant difference. Dotted lines represent MCID (HAQ-DI: ≥ − 0.35; FACIT-F: ≥ − 4.0). CI confidence interval, DLQI Dermatology Life Quality Index, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue scale, HAQ-DI Health Assessment Questionnaire-Disability Index, MCID minimal clinically important difference, NA not applicable, SE standard errorBack to article page